Going concern
Filing comparison
Context Therapeutics Inc. disclosed substantial doubt about its ability to continue as a going concern
No substantial-doubt conclusion identified → Substantial doubt about ability to continue as a going concern
… enerate significant revenues from its current or any future product candidates. The Company believes its cash and cash equivalents of $34.4 million as of September 30, 2026 are not sufficient to fund its projected operations for a period of at least 12 months from the issuance date of these unaudited condensed consolidated financial statements. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The accompanying unaudited condensed…
Evidence
- Blank check
- No
- Comparable
- Yes
- Current state
- substantial_doubt
- Current state label
- Substantial doubt about ability to continue as a going concern
- Direction
- escalated
- Located in
- filing body
- Prior filed
- 2026-08-05
- Prior form
- 10-Q
- Prior state
- none
- Prior state label
- No substantial-doubt conclusion identified
- Source
- ASC 205-40 going-concern note comparison
- Why
- Disclosure about the company's ability to continue as a going concern changed compared with its previous report.